Cargando…

Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases

OBJECTIVE: To evaluate the efficacy of mixed oral prednisolone and intratympanic dexamethasone (ITID) injection in labyrinthitis, due to COVID 19. METHODS: Seventy-five post-COVID-19 labyrinthitis patients were included. Those patients were treated with systemic oral prednisolone for two weeks and I...

Descripción completa

Detalles Bibliográficos
Autores principales: Ismaiel, Wael F., Abdelazim, Mohamed H., Wahba, Ashraf A., Alsobky, Mahmoud E., Ibrahim, Ahmed Abdalrhman, Ghanem, Soliman A., Rabaan, Ali A., Ismail, Elshahat I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384350/
https://www.ncbi.nlm.nih.gov/pubmed/35989722
http://dx.doi.org/10.1016/j.amsu.2022.104429
_version_ 1784769433394216960
author Ismaiel, Wael F.
Abdelazim, Mohamed H.
Wahba, Ashraf A.
Alsobky, Mahmoud E.
Ibrahim, Ahmed Abdalrhman
Ghanem, Soliman A.
Rabaan, Ali A.
Ismail, Elshahat I.
author_facet Ismaiel, Wael F.
Abdelazim, Mohamed H.
Wahba, Ashraf A.
Alsobky, Mahmoud E.
Ibrahim, Ahmed Abdalrhman
Ghanem, Soliman A.
Rabaan, Ali A.
Ismail, Elshahat I.
author_sort Ismaiel, Wael F.
collection PubMed
description OBJECTIVE: To evaluate the efficacy of mixed oral prednisolone and intratympanic dexamethasone (ITID) injection in labyrinthitis, due to COVID 19. METHODS: Seventy-five post-COVID-19 labyrinthitis patients were included. Those patients were treated with systemic oral prednisolone for two weeks and ITID. Patients who refuse ITID were ordered to continue oral prednisolone treatment. Assessment of outcome and audiometry for hearing evaluation was done 1, 2 and 4 weeks as well as 3 months post-treatment. RESULTS: Patients in oral steroid only group were 26 patients, while patients in oral steroid and ITID group were 49 patients. In oral steroid group; 11/26 patients showed complete recovery, 3/26 had partial recovery and 12/26 not recovered. In other group; 38/46 patients had complete recovery, 6 had partial recovery and 5/49 patients not recovered. CONCLUSION: Combined systemic corticosteroid with ITID showed a marked improvement of post-COVID vestibular disorder and hearing loss than only using oral corticosteroid therapy.
format Online
Article
Text
id pubmed-9384350
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93843502022-08-17 Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases Ismaiel, Wael F. Abdelazim, Mohamed H. Wahba, Ashraf A. Alsobky, Mahmoud E. Ibrahim, Ahmed Abdalrhman Ghanem, Soliman A. Rabaan, Ali A. Ismail, Elshahat I. Ann Med Surg (Lond) Cohort Study OBJECTIVE: To evaluate the efficacy of mixed oral prednisolone and intratympanic dexamethasone (ITID) injection in labyrinthitis, due to COVID 19. METHODS: Seventy-five post-COVID-19 labyrinthitis patients were included. Those patients were treated with systemic oral prednisolone for two weeks and ITID. Patients who refuse ITID were ordered to continue oral prednisolone treatment. Assessment of outcome and audiometry for hearing evaluation was done 1, 2 and 4 weeks as well as 3 months post-treatment. RESULTS: Patients in oral steroid only group were 26 patients, while patients in oral steroid and ITID group were 49 patients. In oral steroid group; 11/26 patients showed complete recovery, 3/26 had partial recovery and 12/26 not recovered. In other group; 38/46 patients had complete recovery, 6 had partial recovery and 5/49 patients not recovered. CONCLUSION: Combined systemic corticosteroid with ITID showed a marked improvement of post-COVID vestibular disorder and hearing loss than only using oral corticosteroid therapy. Elsevier 2022-08-17 /pmc/articles/PMC9384350/ /pubmed/35989722 http://dx.doi.org/10.1016/j.amsu.2022.104429 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Cohort Study
Ismaiel, Wael F.
Abdelazim, Mohamed H.
Wahba, Ashraf A.
Alsobky, Mahmoud E.
Ibrahim, Ahmed Abdalrhman
Ghanem, Soliman A.
Rabaan, Ali A.
Ismail, Elshahat I.
Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases
title Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases
title_full Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases
title_fullStr Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases
title_full_unstemmed Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases
title_short Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases
title_sort intratympanic injection of dexamethasone for management of labyrinthitis associated with covid-19 disease resistant cases
topic Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384350/
https://www.ncbi.nlm.nih.gov/pubmed/35989722
http://dx.doi.org/10.1016/j.amsu.2022.104429
work_keys_str_mv AT ismaielwaelf intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases
AT abdelazimmohamedh intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases
AT wahbaashrafa intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases
AT alsobkymahmoude intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases
AT ibrahimahmedabdalrhman intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases
AT ghanemsolimana intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases
AT rabaanalia intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases
AT ismailelshahati intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases